The article examines the objective, findings, and clinical context described in Redefining ARDS for Global Reach and Personalized Care: Part 2.
Approach:
Clinical importance: The editorial reviews ARDS burden, diagnosis, and the role of established interventions in patient care.
Research importance: It considers how definitions shape research inclusion and discusses global representation and treatable traits.
Future directions: It examines the Global Definition of ARDS and the need to combine worldwide applicability with greater biological specificity.
Key Findings:
LUNG SAFE reported ARDS in 10% of ICU patients and 23% of ventilated patients across 50 countries; hospital mortality was 40%. No low-income countries participated.
In a single-center study in Rwanda, ARDS occurred in 4% of adult hospital admissions; 70% of affected patients were cared for entirely outside the ICU, and hospital mortality was 50%.
Low tidal volume ventilation, conservative fluid management, and proning in severe ARDS have demonstrated improved outcomes among ARDS patients.
Definitions determine research inclusion, and the editorial argues that studies should include populations beyond high-income countries because disease characteristics, resources, and treatment effects may differ.
The Global Definition provides a framework applicable worldwide, but remains a clinical syndrome without a clear link to biology or treatable traits.
The authors identify the reliability and necessity of bilateral opacities as an area requiring further investigation.
Interpretation:
The authors call for ARDS definitions and research to support both identification across global settings and personalized approaches based on subphenotypes and treatable traits.
Limitations:
LUNG SAFE did not include low-income countries.
The Rwanda findings cited are from a single center.
The editorial notes that the Global Definition remains syndromic and that further work is needed on bilateral opacities.
Conclusion:
The authors advocate applying the Global Definition to support worldwide participation in ARDS care and research, while refining definitions through research on subphenotypes and treatable traits.
